The prognostic impact of some cell cycle regulatory proteins in egyptian breast cancer patients

• Published in: Journal of Egyptian National Cancer Institute Vol. 18; no. 2; pp. 93 - 102
• Main Authors: al-Basmy, Amani, Zakariyya, Umar, al-Nahhas, Yasir, Yasin, Dina, al-Shakankiry, Nayara, Mukhtar, Nadiyah M., Kamil, Azzah, al-Metnawy, Wafa
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Cairo University, National Cancer Institute 01.06.2006
• Subjects: Biomarkers, Tumor - analysis; Blotting, Western; Breast; Breast Neoplasms - diagnosis; Breast Neoplasms - pathology; Cancer; Carcinoma - diagnosis; Carcinoma - pathology; Cell cycle; Cell Cycle Proteins - analysis; Diagnosis; Egypt; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunohistochemistry; Neoplasm Staging; Prognosis; الثدي; السرطان; دورة الخلية; Egypt
• ISSN: 1110-0362; 1687-9996

Purpose : The particular goal of this work is to study some cell cycle regulatory proteins and their potential impact on prognosis of breast cancer ; p53, cyclin D1 and p27 arc potential effectors being the major contributors to the control of the restriction (R) check point of the cell cycle. We also aimed to evaluate different techniques used to detect these cell cycle proteins. Material and Methods : Forty five breast cancer pa¬tients as well as 10 controls with non malignant pathology were assessed for cell cycle regulators each by 2 different techniques ; p53 was assessed by enzyme immunoassay (EIA) and immunohistochemistry (IHC), cyclin Dl by Western Blotting (WB) and IHC and p27 by WB and IHC. The cut-off was calculated as the mean of the normal controls + 2 SD. Patients were followed up for 4 years and their laboratory data were correlated with different clinical parameters and with other studied regulators. Results : Eighty seven percent of cases (39 / 45) were positive for p53 by EIA with a range from 20 to 4300, and a mean of 464 + 97lpg / mg protein. By IHC, 80 % (24 / 30) of the cases showed varying degrees of positivity. Using WB, cyclin Dl showed high expression levels above cut off values in 69 % of patients (31 / 45) and in 67 % (20 / 30) by IHC. The corresponding positive figures for p27 were 82 % (37 / 45) and 73 % (22 / 30) using the two techniques, respectively. No significant association was found between p53, cyclin Dl and p27 on one side and different clinical parameters as lymph node status, tumor size or presence of distant metastases on the other side. Survival was poor in patients with high p53 expression. Cyclin Dl positive cases showed comparable survival with negative cases, whereas high p27 levels favored a longer disease free survival. Conclusions : Techniques more suitable for assessment of each of these markers in our consideration were EIA for p53, WB for cyclin Dl and IHC for p27. Moreover, this study demonstrated that these markers were relevant to the biological behavior of the tumor cell per se with a possible impact on prognosis and survival, independent of other clinical prognostic factors.